Immutep not only leads the way with its LAG-3 research but sets the research standard because it was discovered by its Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. This alone has put Immutep as a global leader of immunotherapy drugs for cancer and autoimmune diseases.
“It’s really what we do. We are a LAG-3 company. We have more programs built around LAG-3 than even anyone, including in the Pharma space,” said Immutep CEO Marc Voigt. “The reality is, there has not been a new, approved or validated checkpoint in the past six years. LAG-3 is our opportunity to be the next big thing in immunization technology.”
Some pretty confident statements made there
Interesting read, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.5¢ | $694.0K | 2.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 22530 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 176372 | 4 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |